Tadashi Namisaki Selected Research

Insulin Resistance

8/2020	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
4/2020	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males.
9/2019	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.
6/2019	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
8/2013	Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
4/2010	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
5/2009	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
1/2009	Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tadashi Namisaki Research Topics

Disease

57	Liver Cirrhosis (Hepatic Cirrhosis) 03/2024 - 10/2002
49	Fibrosis (Cirrhosis) 03/2024 - 10/2002
32	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 09/2003
27	Neoplasms (Cancer) 04/2024 - 06/2003
17	Fatty Liver 12/2023 - 10/2006
12	Liver Diseases (Liver Disease) 12/2023 - 01/2009
12	Non-alcoholic Fatty Liver Disease 11/2023 - 10/2006
10	Alcoholic Fatty Liver 10/2022 - 07/2008
8	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 12/2022 - 01/2017
8	Insulin Resistance 08/2020 - 01/2009
8	Carcinogenesis 03/2020 - 07/2003
7	Sarcopenia 12/2023 - 01/2020
6	Inflammation (Inflammations) 12/2023 - 01/2013
5	Hyperammonemia 08/2022 - 12/2017
5	Hepatic Encephalopathy 12/2021 - 12/2017
4	Cholangitis 04/2025 - 02/2018
4	Thrombophilia 02/2024 - 05/2019
4	Atrophy 12/2023 - 12/2021
4	Ascites 05/2023 - 08/2017
4	Liver Neoplasms (Liver Cancer) 01/2023 - 12/2014
4	Alcoholic Liver Diseases (Alcoholic Liver Disease) 12/2021 - 01/2013
4	Infections 06/2021 - 01/2017
3	Thrombosis (Thrombus) 02/2024 - 08/2017
3	Hypertension (High Blood Pressure) 10/2023 - 11/2017
3	Chronic Hepatitis B 10/2023 - 09/2017
3	Chronic Hepatitis (Chronic Active Hepatitis) 10/2023 - 11/2018
3	Type 2 Diabetes Mellitus (MODY) 10/2023 - 02/2016
3	Autoimmune Hepatitis 07/2023 - 06/2021
3	Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis) 06/2023 - 07/2021
3	Acute-On-Chronic Liver Failure 01/2023 - 05/2020
3	Hemorrhage 01/2023 - 01/2017
3	Cholangiocarcinoma 01/2023 - 10/2018
3	Muscle Cramp (Cramp) 12/2020 - 01/2019
2	Choledocholithiasis 04/2025 - 10/2021
2	COVID-19 04/2025 - 11/2023

Drug/Important Bio-Agent (IBA)

18	Biomarkers (Surrogate Marker)IBA 02/2024 - 07/2003
17	Amino Acids FDA Link 10/2023 - 07/2003
15	Choline (Choline Chloride)IBA 12/2023 - 07/2003
15	EndotoxinsIBA 12/2023 - 01/2013
14	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 12/2003
11	CDAA (Randox)IBA 10/2022 - 07/2003
10	LipopolysaccharidesIBA 04/2024 - 08/2017
10	von Willebrand FactorIBA 02/2024 - 02/2018
9	Losartan (Cozaar)FDA LinkGeneric 12/2023 - 05/2009
8	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/2024 - 02/2016
8	Angiotensin IIIBA 12/2023 - 09/2003
8	CytokinesIBA 08/2022 - 05/2006
8	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 08/2010 - 12/2003
7	Carbon Tetrachloride (Tetrachloromethane)IBA 03/2024 - 01/2017
7	Proteins (Proteins, Gene)FDA Link 12/2023 - 10/2002
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2023 - 09/2017
7	Angiotensin II Type 1 Receptor BlockersIBA 01/2022 - 05/2009
7	CollagenIBA 10/2020 - 12/2008
7	Glutathione Transferase (Glutathione S-Transferase)IBA 06/2018 - 07/2003
6	EnzymesIBA 02/2024 - 07/2003
6	Messenger RNA (mRNA)IBA 04/2023 - 10/2002
6	Rifaximin (L 105)FDA Link 10/2022 - 12/2017
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2010 - 12/2003
5	lenvatinibIBA 04/2024 - 01/2021
5	Angiotensin Receptor AntagonistsIBA 12/2023 - 10/2014
5	ZincIBA 07/2023 - 06/2021
5	Toll-Like Receptor 4IBA 10/2022 - 06/2019
5	Branched-Chain Amino AcidsIBA 12/2021 - 01/2009
5	Glucose (Dextrose)FDA LinkGeneric 03/2020 - 11/2017
4	AntigensIBA 01/2023 - 12/2020
4	AlbuminsIBA 10/2022 - 01/2017
4	Anti-Bacterial Agents (Antibiotics)IBA 12/2021 - 03/2015
4	Carrier Proteins (Binding Protein)IBA 10/2021 - 09/2017
4	Antiviral Agents (Antivirals)IBA 08/2020 - 01/2017
4	Sorafenib (BAY 43-9006)FDA Link 12/2019 - 10/2014
4	AldosteroneIBA 08/2017 - 05/2010
3	Interleukin-8 (Interleukin 8)IBA 04/2024 - 07/2005
3	Ethanol (Ethyl Alcohol)IBA 12/2023 - 01/2021
3	Hydroxyproline (4 Hydroxyproline)IBA 04/2023 - 02/2005
3	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2023 - 10/2016
3	Gemcitabine FDA Link 01/2023 - 08/2009
3	Tolvaptan FDA Link 05/2022 - 08/2017
3	Hyaluronic Acid (Hyaluronan)IBA 10/2021 - 08/2020
3	Tissue Inhibitor of MetalloproteinasesIBA 10/2021 - 08/2020
3	Matrix Metalloproteinases (MMPs)IBA 06/2021 - 10/2002
3	AntioxidantsIBA 06/2021 - 12/2020
3	DiureticsIBA 01/2021 - 08/2017
3	Therapeutic UsesIBA 12/2020 - 01/2008
3	Insulin (Novolin)FDA Link 04/2020 - 02/2016
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2019 - 02/2016
3	InterferonsIBA 09/2018 - 01/2008
3	Transforming Growth Factor beta (TGF-beta)IBA 12/2016 - 05/2006
3	Chelating AgentsIBA 06/2011 - 09/2003
3	Perindopril FDA LinkGeneric 05/2006 - 12/2003
3	Tissue Inhibitor of Metalloproteinase-1IBA 09/2003 - 10/2002
2	AnticoagulantsIBA 04/2025 - 09/2020
2	ThrombospondinsIBA 02/2024 - 05/2019
2	Metalloproteases (Metalloproteinases)IBA 02/2024 - 05/2019
2	DisintegrinsIBA 02/2024 - 05/2019
2	Tight Junction ProteinsIBA 12/2023 - 08/2020

Therapy/Procedure

18	Therapeutics 05/2023 - 02/2005
8	Drug Therapy (Chemotherapy) 01/2023 - 12/2014
8	Oral Administration 10/2022 - 05/2005
4	Chemoprevention 10/2014 - 05/2005
3	Intraperitoneal Injections 01/2021 - 01/2019